In disease contexts, such as autoimmunity, cancer, atherosclerosis and fibrosis, where PADI4 expression or activity are aberrantly high, a potent and selective inhibitor, which is specific for the active form, is likely to be highly advantageous. Here, PADI4 is linked to cancer.